ClinicalTrials.Veeva

Menu

Venetoclax in Combination with 5 Days Azacitidine in Untreated AML Patients, Not Eligible for Standard Induction Therapy (VENAZA-5S)

U

University of Leipzig

Status and phase

Enrolling
Phase 2

Conditions

Acute Myeloid Leukemia (AML)

Treatments

Drug: VEN+AZA-5

Study type

Interventional

Funder types

Other
Industry

Identifiers

NCT05833438
VENAZA-5S
2022-501537-23-00 (Other Identifier)

Details and patient eligibility

About

Acute myeloid leukemia (AML): continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cycle = standard of care for intensive induction therapy ineligible AML patients in Germany

The VENAZA-5S pilot trial: AZA administration reduced to 5 days within each cycle to improve tolerability and treatment adherence due to less neutropenic infections, less treatment interruptions and less hospitalizations.

Full description

Acute myeloid leukemia (AML) is a uniformly fatal disease if untreated. The combination of continuous oral Venetoclax (VEN) and 7 days of s.c. Azacitidine (AZA) per 28-day cycle has recently emerged as the new standard of care for AML patient who are ineligible for intensive induction therapy, and has been widely adopted in Germany.

The VENAZA-5S pilot trial aims to reduce the reported hematological toxicity profile of this currently approved combination, while preserving efficacy, by modifying AZA administration to 5 days within each cycle. The hypothesis is that this modification will not interfere with the response rates achieved by the combination, but will rather improve tolerability and treatment adherence due to less neutropenic infections, less treatment interruptions and hospitalizations, and thus result in better quality of life and favorable long-term outcomes in elderly or comorbid AML patients. This single-arm pilot study is intended to generate first data on the efficacy and toxicity of 5 days AZA + VEN, which will be compared to a historical control cohort treated with the current standard of 7 days AZA + VEN.

Enrollment

45 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion and exclusion criteria

Key Inclusion Criteria:

  • Confirmed diagnosis of AML by World Health Organization (WHO) criteria 2016
  • Ineligible for treatment with a standard cytarabine and anthracycline induction regimen due to age or comorbidities
  • Age ≥ 18 years
  • Life expectancy of at least 12 weeks

Key Exclusion Criteria:

  • Prior treatment for AML or myelodysplastic syndrome (MDS) with one of the following:

    • Hypomethylating agent (HMA)
    • Chemotherapeutic agent
    • Chimeric Antigen Receptor (CAR)-T cell therapy
    • Experimental therapies
    • Note: Prior use of hydroxyurea is allowed
  • History of myeloproliferative neoplasm (MPN)

  • Diagnosis of acute promyelocytic leukemia (APL)

  • Presence of favorable-risk karyotype abnormalities: t(15;17), t(8;21), inv(16) or t(16;16)

Trial design

Primary purpose

Treatment

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

45 participants in 1 patient group

VEN+AZA-5
Experimental group
Description:
Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)
Treatment:
Drug: VEN+AZA-5

Trial contacts and locations

10

Loading...

Central trial contact

Klaus Metzeler, Prof. Dr.; Uwe Platzbecker, Prof. Dr.

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems